Trial results today are reshaping pharma fortunes, with clinical successes boosting confidence while failures trigger sharp market reactions.
Pharma Today tracks how capital, investment and biosimilars shape new moves across India’s drug industry, with Sun Pharma, ChrysCapital and Lupin advancing distinct growth priorities.
Tylenol exposure in pregnancy draws fresh scrutiny as the latest evidence links prenatal exposure to reproductive changes in daughters.
The obesity drug market swings between big wins and bigger doubts as new trial results, rising sales and treatment limits reshape the industry.
.jpg)
India’s pharma industry is looking beyond generics, but regulatory standards could determine how quickly it attracts global investment in innovation. Commerce and Industry Minister Piyush Goyal has called for greater alignment with developed...
Acquisitions and manufacturing steal the spotlight today as pharma companies pursue strategic deals, capacity expansion, and stronger market reach.
The global race to outpace cancer is accelerating, with MedGenome, HUTCHMED, AbbVie and Cipla advancing detection, treatment, survival and access.
Pharma companies are advancing critical care with innovative drugs, rare-disease research, and preventive diagnostics to address unmet needs.
India's cancer challenge is growing, while breakthrough therapies today offer new hope for patients through earlier detection and innovation.
Autoimmune therapies, oncology advances, and major takeovers take center stage as three significant biologics deals reshape industry pipelines today
.jpg)
, CDSCO.jpg)
